Title | Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Holstein, SA, J Ye, C, Howard, A, Bhutani, M, Gormley, N, Hahn, T, Hillengass, J, Krishnan, A, C Landgren, O, Munshi, NC, Oliva, S, Owen, RG, Pasquini, MC, Puig, N, Weinhold, N, Weisel, K, McCarthy, PL |
Journal | Biol Blood Marrow Transplant |
Volume | 25 |
Issue | 3 |
Pagination | e89-e97 |
Date Published | 2019 03 |
ISSN | 1523-6536 |
Keywords | Bone Marrow Transplantation, Clinical Trials as Topic, Congresses as Topic, Education, Humans, Immunologic Factors, Multiple Myeloma, Neoplasm, Residual, Societies, Scientific |
Abstract | The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice. |
DOI | 10.1016/j.bbmt.2018.11.001 |
Alternate Journal | Biol Blood Marrow Transplant |
PubMed ID | 30408566 |
PubMed Central ID | PMC6445685 |
Grant List | U10 HL069294 / HL / NHLBI NIH HHS / United States UG1 HL069249 / HL / NHLBI NIH HHS / United States U24 CA076518 / CA / NCI NIH HHS / United States U24 HL138660 / HL / NHLBI NIH HHS / United States UG1 HL069278 / HL / NHLBI NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States R01 HL107213 / HL / NHLBI NIH HHS / United States |